A clinical study of XRx-026 for the treatment of individuals who have gout and are intolerant to allopurinol
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs XRx 026 (Primary)
- Indications Gout
- Focus Adverse reactions
- 13 Jan 2025 New trial record
- 06 Jan 2025 According to XORTX Therapeutics media release, XORTX is initiating discussions for the XRx-026 program with the US Food and Drug Administration (FDA) regarding preparation of a New Drug Application (NDA), NDA filing is planned for first half 2025.Pending FDA feedback, the Company will also seek FDA orphan drug designation and NDA marketing approval for the XRx-026 program.